Smarca degraders and uses thereof

Patent metadata

Field	Value
Publication number	US-2024343724-A1
Application number	US-202118265595-A
Country	US
Kind code	A1
Filing date	Dec 9, 2021
Priority date	Dec 9, 2020
Publication date	Oct 17, 2024
Grant date	—

Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

First claim

1 - 21 . (canceled)

22 . A compound selected from:

or a pharmaceutically acceptable salt thereof.

23 . A pharmaceutical composition comprising a compound according to claim 22 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

24 . The pharmaceutical composition according to claim 23 , further comprising an additional therapeutic agent.

25 . A method of degrading one or more of SMARCA2, SMARCA4, and PB1 protein in a patient or biological sample comprising administering to said patient, or contacting said biological sample with a compound according to claim 22 , or a pharmaceutical composition thereof.

26 . A method of treating one or more SMARCA2-mediated, SMARCA4-mediated, or PB1-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound according claim 22 , or a pharmaceutical composition thereof.

27 . The method according to claim 26 , further comprising administration of an additional therapeutic agent.

28 . The method according to claim 26 , wherein the one or more SMARCA2-mediated, SMARCA4-mediated, or PB1-mediated disorder, disease or condition is selected from a cancer, a neurodegenerative disease, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a metabolic disorder, a condition associated with organ transplantation, an immunodeficiency disorder, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, a pathologic immune condition involving T cell activation, a cardiovascular disorder, and a CNS disorder.

29 . The method according to claim 28 , wherein the cancer is selected from lung cancer, non-small cell lung cancer (NSCLC), small-cell lung cancer, glioma, breast cancer, pancreatic cancer, colorectal cancer, bladder cancer, endometrial cancer, penile cancer, esophagogastric cancer, hepatobiliary cancer soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carsinoma, bone cancer, non-Hodgkin lymphoma, prostate cancer, embryonal tumors, germ cell tumors, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumor, uterine sarcoma, gastrointestinal stromal tumor, CNS cancer, thymic tumor, adrenocortical carcinoma, appendiceal cancer, small bowel cancer, non-melanoma skin cancer, melanoma, leukemia, and malignant rhabdoid tumors (MRT).

Assignees

• Kymera Therapeutics Inc

Inventors

• Zhang Yi
• Zheng Xiaozhang
• Zhu Xiao

Classifications

• A61K31/454

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D417/14 Primary

  containing three or more hetero rings · CPC title